Takeda Pharmaceutical Company Limited (TAK)

NYQ – Real vaqt narxi. Valyuta: USD

16.42

+0.06 (0.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

16.45

+0.03 (0.15%)

Bozor oldidan: May 13, 2026, 4:22 AM EDT

13.05.2026

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was parti.

04.05.2026

Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Pharmaceutical said its ‌experimental drug for primary immunodeficiency disease, ⁠a rare condition that weakens the immune system, has met ‌the ⁠main goal of a mid- to ⁠late-stage clinical trial.

04.05.2026

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.

30.04.2026

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

24.04.2026

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.

14.04.2026

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

13.04.2026

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Autoimmune diseases, oncology, and type 2 diabetes continue to spread around the world, but these stocks stay off investors' radars. Many of them consistently beat Street's consensus forecasts and offer dividend yields even higher than oil and gas stocks, as well as the "Magnificent 7." By opening this article, you will find out my "top 4 Big Pharma players."

Videolar

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Press-relizlar

13.05.2026

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

04.05.2026

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.

28.03.2026

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care.

02.03.2026

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act.

Takeda Pharmaceutical Company Limited (TAK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Takeda Pharmaceutical Company Limited (TAK)

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Videolar

Press-relizlar

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Videolar

Press-relizlar

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Search stocks

Takeda Pharmaceutical Company Limited (TAK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Takeda Pharmaceutical Company Limited (TAK)

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Videolar

Press-relizlar

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda's immune disease drug meets main goal of mid-to-late stage trial

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Videolar

Press-relizlar

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera